Project Grant R03NS139000
- Federal Project Grant Award Summary Columbia University's Health Sciences Division received a $660,613 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective June 1, 2026 through March 31, 2031. The research focuses on developing and validating spinal cord stimulation (SCS) as a combination therapy to enhance motor function in patients with...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $1,049,035 to The Children's Hospital of Philadelphia Research Institute on June 1, 2025, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). This two-year project, concluding May 31, 2027, supports database harmonization and creation of outcome assessment and prediction tools for metachromatic leukodystrophy (MLD), a rare,...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $1,702,003.00 to develop and assess the clinical potential of quantitative imaging biomarkers for evaluating changes in myofiber microstructure associated with masticatory myofascial pain syndrome (MMPS). The key products and services to be delivered include: 1) Establishing an optimal 15-minute MRI protocol and...
- Federal Project Grant Award Summary The Children's Hospital of Philadelphia Research Institute received a $489,500 project grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on September 3, 2025, with a completion date of September 2, 2027. This award supports the development of patient-centric clinical outcome measures for Multiple Sulfatase Deficiency (MSD), an ultra-rare, fatal neurodegenerative disorder. The project addresses a critical gap in...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant totaling $151,760 to The Trustees of Columbia University in the City of New York (Health Sciences Division) effective November 1, 2026, through October 31, 2028, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The research investigates targeting the CCR5 (C-C Chemokine Receptor Type 5) receptor as a...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded $446,991 to the University of California, Los Angeles under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853) on August 7, 2025, with completion scheduled for July 31, 2027. This Project Grant supports the development of a novel diagnostic assay for identifying parkinsonian tauopathies, specifically progressive supranuclear palsy...
- Summary Thomas Jefferson University, operating as Sidney Kimmel Medical College, received a $196,250 Project Grant awarded June 2, 2026, by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The grant supports research development of an innovative diagnostic test to detect early respiratory impairments in amyotrophic lateral sclerosis (ALS). The research will combine...
- Federal Grant Award Summary The Medical University of South Carolina (MUSC) received a $427,814 Project Grant from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) to conduct research examining whether operant conditioning of motor evoked potentials (MEP) to transcranial magnetic stimulation (TMS) can improve corticospinal pathway recruitment in individuals with chronic cervical spinal cord...
- Federal Project Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $669,891 Project Grant to the Icahn School of Medicine at Mount Sinai on February 3, 2026, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award funds a comprehensive five-year research initiative (through January 30, 2031) investigating the genetic, transcriptomic, and immunohistochemical basis of Progressive...
- Federal Project Grant Award Summary Rutgers The State University of New Jersey received a $429,514 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded September 1, 2025, with completion anticipated by August 31, 2027. The research will be conducted at the institution's location in New Jersey and focuses on investigating myelin acquisition and...
ASSESSMENT OF CERVICAL SPINAL PATHOLOGY IN PATIENTS WITH MPS I, II AND VI - ABSTRACT CERVICAL SPINE ABNORMALITIES IN MUCOPOLYSACCHARIDOSIS (MPS) MAY RESULT IN CERVICAL SPINAL CORD (CSC) COMPRESSION AND IRREVERSIBLE NEUROLOGICAL DISABILITY. MRI SIGNAL INTENSITY CHANGES IN CSC IMAGES OCCUR IN THE PRESENCE OF ADVANCED STENOSIS, MYELOPATHY, AND DEVELOPED CLINICAL SYMPTOMS. THE PROPOSAL PRESUMES THAT DEFICITS IN CSC MORPHOLOGY AND MICROSTRUCTURE PRECEDE MRI SIGNAL CHANGES AND ARE PREDICTIVE OF CLINICAL MYELOPATHY. WE WILL PROCEED WITH SYSTEMATIC VALIDATION COMPARING CSC MORPHOLOGY AND MICROSTRUCTURE IN MPS PATIENTS AND CASE-MATCHED HEALTHY CONTROLS. THE OVERALL OBJECTIVE IS TO ANALYZE EXISTING AND ACQUIRED CSC MRI DATA AND ASSESS LONGITUDINAL CSC MORPHOLOGY AND CROSS-SECTIONAL CSC MICROSTRUCTURE IN THE MPS. THE CENTRAL HYPOTHESIS IS THAT QUANTITATIVE MRI IS SENSITIVE TO CSC MORPHOLOGICAL AND MICROSTRUCTURAL DEGENERATION, MYELOPATHY RISK, AND DISEASE SEVERITY IN MPS. TO TEST THE CENTRAL HYPOTHESIS AND, THEREBY, ATTAIN THE OVERALL OBJECTIVE, WE WILL PURSUE TWO SPECIFIC AIMS: AIM 1: ASSESS LONGITUDINAL MORPHOLOGICAL DAMAGE OF CSC IN MPS TYPES I, II, AND VI AND AIM 2: ASSESS CROSS-SECTIONAL MICROSTRUCTURAL DAMAGE OF CSC IN MPS TYPES I AND VI. AIM 1 WILL TEST A WORKING HYPOTHESIS THAT CSC MORPHOLOGY IS ALTERED DUE TO CERVICAL SPINAL COMPRESSION AND IS PREDICTIVE OF MYELOPATHY IN MPS. AIM 2 WILL TEST A WORKING HYPOTHESIS THAT CSC INNER INTEGRITY IS ALTERED DUE TO MPS I AND VI DISEASES. WE WILL DEMONSTRATE THAT QUANTITATIVE CSC MRI MEASUREMENTS ARE PROPORTIONAL TO MYELOPATHY RISK AND DISEASE SEVERITY IN MPS. THE EFFECTS OF MPS TREATMENT ON CSC MEASUREMENTS WILL BE INVESTIGATED WHERE POSSIBLE. THE PROPOSAL WILL IDENTIFY CANDIDATES FOR BIOMARKERS OF MYELOPATHY IN MPS. REGARDING THE BIOMARKER RESEARCH, THE PROPOSAL IS A PILOT PRECLINICAL EXPLORATORY PHASE 1. THE PROJECT IS INNOVATIVE BECAUSE IT WILL: (I) DISCOVER THE BIOMARKER CANDIDATES OF MYELOPATHY RISK AND DISEASE SEVERITY IN MPS; (II) DIFFUSION TENSOR IMAGING (DTI) WILL BE ASSESSED IN THE CSC OF MPS PATIENTS; (III) DEMONSTRATE THAT DTI-BASED CSC MICROSTRUCTURE CAN ASSESS ONGOING DEGENERATIVE PROCESSES BEFORE VISUAL AND QUALITATIVE MRI SIGNAL INTENSITY CHANGES. OVERALL, THE PROPOSAL AIMS TO ADVANCE OBJECTIVE EARLY MYELOPATHY DIAGNOSIS, WHICH CAN GUIDE THE TIMING OF A PROPHYLACTIC MYELOPATHY TREATMENT AND IMPROVE CLINICAL OUTCOMES IN MPS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $155.0k | 6/28/24 |